Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Accumulated Expenses (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Other Accumulated Expenses data on record, last reported at $721000.0 in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 71.26% year-over-year to $721000.0; the TTM value through Dec 2025 reached $721000.0, up 71.26%, while the annual FY2025 figure was $721000.0, 71.26% up from the prior year.
  • Other Accumulated Expenses reached $721000.0 in Q4 2025 per SNDX's latest filing, up from $595000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.2 million in Q3 2022 and bottomed at $188000.0 in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $927750.0, with a median of $611000.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: soared 1594.68% in 2022, then tumbled 83.13% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.7 million in 2021, then tumbled by 64.49% to $604000.0 in 2022, then soared by 47.02% to $888000.0 in 2023, then plummeted by 52.59% to $421000.0 in 2024, then skyrocketed by 71.26% to $721000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $721000.0 in Q4 2025, $595000.0 in Q3 2025, and $618000.0 in Q2 2025.